PMID- 34345194
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220425
IS  - 1179-5514 (Print)
IS  - 1179-5514 (Electronic)
IS  - 1179-5514 (Linking)
VI  - 14
DP  - 2021
TI  - Real-World Clinical Experience on the Usage of High-Dose Metformin (1500-2500 
      mg/day) in Type 2 Diabetes Management.
PG  - 11795514211030513
LID - 10.1177/11795514211030513 [doi]
LID - 11795514211030513
AB  - BACKGROUND: To evaluate the clinical characteristics, treatment patterns, and 
      clinical effectiveness and safety of high doses of metformin (1500-2500 mg/day) 
      in Indian adults with type 2 diabetes mellitus (T2DM). MATERIALS AND METHODS: A 
      retrospective, multicentric (n = 241), real-world study included patients with 
      T2DM (aged >18 years) receiving high doses of metformin. Details were retrieved 
      from patient's medical records. RESULTS: Out of 5695 patients, 62.7% were men 
      with median age was 50.0 years. Hypertension (67.5%) and dyslipidemia (48.7%) 
      were the prevalent comorbidities. Doses of 2000 mg (57.4%) and 1500 mg (29.1%) 
      were the most commonly used doses of metformin and median duration of high-dose 
      metformin therapy was 24.0 months. Metformin twice daily was the most frequently 
      used dosage pattern (94.2%). Up-titration of doses was done in 96.8% of patients. 
      The mean HbA1c levels were significantly decreased post-treatment (mean change: 
      1.08%; P < .001). The target glycemic control was achieved in 91.2% patients. A 
      total of 83.0% had decreased weight. Adverse events were reported in 156 
      patients. Physician global evaluation of efficacy and tolerability showed 
      majority of patients on a good to excellent scale (98.2% and 97.7%). CONCLUSION: 
      Clinical effectiveness and safety of a high-dose metformin was demonstrated 
      through significant improvement in HbA1c levels and weight reduction.
CI  - (c) The Author(s) 2021.
FAU - Das, Ashok Kumar
AU  - Das AK
AD  - Pondicherry Institute of Medical Sciences, Pondicherry, India.
FAU - Shah, Sanjiv
AU  - Shah S
AD  - Apollo Sugar Clinic, Mumbai, Maharashtra, India.
FAU - Singh, Santosh Kumar
AU  - Singh SK
AD  - Dr. Santosh Kumar Singh's Clinic, Patna, Bihar, India.
FAU - Juneja, Archana
AU  - Juneja A
AD  - Kokilaben Dhirubhai Ambani Hospital of Medical Sciences, Mumbai, Maharashtra, 
      India.
FAU - Mishra, Niroj Kumar
AU  - Mishra NK
AD  - Kar Clinic & Hospital Pvt. Ltd., Bhubaneswar, Odisha, India.
FAU - Dasgupta, Arundhati
AU  - Dasgupta A
AD  - Rudraksh Superspeciality Care, Siliguri, West Bengal, India.
FAU - Deka, Nilakshi
AU  - Deka N
AD  - Apollo Hospital, Guwahati, Assam, India.
FAU - Abhyankar, Mahesh
AU  - Abhyankar M
AUID- ORCID: 0000-0003-3127-0575
AD  - Scientific Services, USV Private Limited, Mumbai, Maharashtra, India.
FAU - Revankar, Santosh
AU  - Revankar S
AD  - Scientific Services, USV Private Limited, Mumbai, Maharashtra, India.
LA  - eng
PT  - Journal Article
DEP - 20210713
PL  - United States
TA  - Clin Med Insights Endocrinol Diabetes
JT  - Clinical medicine insights. Endocrinology and diabetes
JID - 101578235
PMC - PMC8280839
OTO - NOTNLM
OT  - HbA1c reduction
OT  - obesity
OT  - treatment patterns
OT  - up-titration
COIS- Declaration of conflicting interests: The author(s) declared the following 
      potential conflicts of interest with respect to the research, authorship, and/or 
      publication of this article: Dr. Mahesh Abhyankar and Dr. Santosh Revankar are 
      employees of USV Pvt. Ltd. All other authors have no conflicts of interest to 
      declare.
EDAT- 2021/08/05 06:00
MHDA- 2021/08/05 06:01
PMCR- 2021/07/13
CRDT- 2021/08/04 07:05
PHST- 2021/02/06 00:00 [received]
PHST- 2021/06/17 00:00 [accepted]
PHST- 2021/08/04 07:05 [entrez]
PHST- 2021/08/05 06:00 [pubmed]
PHST- 2021/08/05 06:01 [medline]
PHST- 2021/07/13 00:00 [pmc-release]
AID - 10.1177_11795514211030513 [pii]
AID - 10.1177/11795514211030513 [doi]
PST - epublish
SO  - Clin Med Insights Endocrinol Diabetes. 2021 Jul 13;14:11795514211030513. doi: 
      10.1177/11795514211030513. eCollection 2021.